Methods and nucleic acid molecules for aav vector selection
US-2024417717-A1 · Dec 19, 2024 · US
US9550813B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9550813-B2 |
| Application number | US-201314401754-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 22, 2013 |
| Priority date | May 22, 2012 |
| Publication date | Jan 24, 2017 |
| Grant date | Jan 24, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Intermolecular disulfide stabilized foldon polypeptides are provided.
Opening claim text (preview).
What is claimed is: 1. A cysteine-substituted foldon polypeptide, wherein two amino acids of a native foldon polypeptide are substituted with cysteine residues that can form intermolecular disulfide bonds when the foldon is in a trimeric quaternary structure, wherein the native foldon polypeptide has the amino acid sequence set forth in SEQ ID NO:1 and wherein the amino acid substitutions are selected from [G10C, D17C]; [R8C, D17C]; [R8C, G18C]; [P7C, G18C]; [A12C, K16C]; and [Y13C, R15C]. 2. The cysteine-substituted foldon polypeptide of claim 1 , wherein the amino acid substitutions are selected from [A12C, K16C]; [R8C, D17C]; and [R8C, G18C]. 3. The cysteine-substituted foldon polypeptide of claim 1 , wherein the cysteine-substituted foldon polypeptide is a monomer. 4. The cysteine-substituted foldon polypeptide of claim 1 , wherein the cysteine-substituted foldon polypeptide is a trimer. 5. The cysteine-substituted foldon polypeptide of claim 1 , wherein the cysteine-substituted foldon polypeptide is joined to a fusion partner. 6. The cysteine-substituted foldon polypeptide of claim 5 , wherein the fusion partner is a viral antigen. 7. The cysteine-substituted foldon polypeptide of claim 1 , further comprising one or more of a tag for purification, an unnatural amino acid, and site for protease cleavage. 8. The cysteine-substituted foldon polypeptide of claim 7 , wherein the cysteine-substituted foldon polypeptide is a fusion protein, and comprises at least one unnatural amino acid at a defined site. 9. The cysteine-substituted foldon polypeptide of claim 8 , where the cysteine-substituted foldon polypeptide is a trimer, and the unnatural amino acid is used to covalently join one chain of the trimer to a virus like particle. 10. A method of producing a cysteine-substituted foldon polypeptide according to claim 1 , comprising introducing a polynucleotide sequence encoding the cysteine-substituted foldon polypeptide operably linked to a promoter, into a cell or cell free protein synthesis reaction mix and incubating for a period of time sufficient to synthesize the protein.
containing protease site · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin · CPC title
New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes · CPC title
containing a Strep-tag · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.